Our Q&As are emailed in our Saturday Morning Report, find the answer to this question below.
Hi MM Team Thx for your continuing good work. With the latest news this week from TLX for an agreed schedule with FDA for re-submission of their latest treatment for approval. The Mkt has hammered them hard this year so we’re down around $14. What is you view of TLX’s position & is it about time to invest again? Kind regards Glenn
Hi Glenn,
As a bio tech, albeit a well-established $4.7bn company, volatility is to be expected but its aggressive decline has surprised even us who generally avoids the space due to the succession of binary outcomes – we thought it was looking interesting below $20, now it’s struggling to hold above $14.
In 2025, TLX has faced regulatory setbacks, including FDA rejections (CRLs) for its kidney and brain cancer imaging agents due to manufacturing and data concerns. The company also disclosed an SEC subpoena related to its disclosures on prostate cancer therapies, triggering an additional sharp share price drop. These issues have shaken investor confidence to the point where is starting to feel like it cannot get any worse!
We think it still looks interesting here, with the market basically applying no value to new products. It does feel like accumulating into current weakness will pay dividends over the next 6-12 months but it’s not for the fainthearted. It’s one we’re looking at now for the Emerging Companies Portfolio.
Take a free trial.
No payment details required.
Forgot password? Request a One Time Password or reset your password
One Time Password
Check your email for an email from [email protected]
Subject: Your OTP for Account Access
This email will have a code you can use as your One Time Password for instant access
A link to create a new password will be sent to the email address you have registered to your account.
Hi, this is only available to members. Join today and access the latest views on the latest developments from a professional money manager.
Our Smart Phone App will give you access to much of our content and notifications. Download for free today.
